Rossella Cianci

Dr. Rossella Cianci

Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore
orcid

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2015 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
SFSimona Frosali
Simona Frosali
Danilo PagliariDanilo Pagliari
Danilo Pagliari
GGGiovanni Gambassi
Giovanni Gambassi
RLRaffaele Landolfi
Raffaele Landolfi
Franco PandolfiFranco Pandolfi
Franco Pandolfi
Rossella CianciRossella Cianci
Rossella Cianci
The gut is able to maintain tolerance to microbial and food antigens. The intestine minimizes the number of harmful bacteria by shaping the microbiota through a symbiotic relationship. In healthy human intestine, a constant homeostasis is maintained by the perfect regulation of microbial load and the immune response generated against it. Failure of this balance may result in various pathological conditions. Innate immune sensors, such as Toll-like receptors (TLRs), may be considered an interface among intestinal epithelial barrier, microbiota, and immune system. TLRs pathway, activated by pathogens, is involved in the pathogenesis of several infectious and inflammatory diseases. The alteration of the homeostasis between physiologic and pathogenic bacteria of intestinal flora causes a condition called dysbiosis. The breakdown of homeostasis by dysbiosis may increase susceptibility to inflammatory bowel diseases. It is evident that environment, genetics, and host immunity form a highly interactive regulatory triad that controls TLR function. Imbalanced relationships within this triad may promote aberrant TLR signaling, critically contributing to acute and chronic intestinal inflammatory processes, such as in IBD, colitis, and colorectal cancer. The study of interactions between different components of the immune systems and intestinal microbiota will open new horizons in the knowledge of gut inflammation.

1 May 2015 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
GCGiovanni Cammarota
Giovanni Cammarota
Gianluca IaniroGianluca Ianiro
Gianluca Ianiro
Rossella CianciRossella Cianci
Rossella Cianci
Stefano BibbòStefano Bibbò
Stefano Bibbò
AGAntonio Gasbarrini
Antonio Gasbarrini
DCDiego Curro'
Diego Curro'

1 October 2000 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
GCG. Cammarota
G. Cammarota
Rossella CianciRossella Cianci
Rossella Cianci
OCO. Cannizzaro
O. Cannizzaro
LCL. Cuoco
L. Cuoco
GPG. Pirozzi
G. Pirozzi
GGG. Gasbarrini
G. Gasbarrini

1 October 2000 in The Lancet
Verified
Journal Article
Closed access
GCGiovanni Cammarota
Giovanni Cammarota
LCLucio Cuoco
Lucio Cuoco
Rossella CianciRossella Cianci
Rossella Cianci
Franco PandolfiFranco Pandolfi
Franco Pandolfi
GGGiovanni Gasbarrini
Giovanni Gasbarrini

1 September 2010 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Closed access
GCGiovanni Cammarota
Giovanni Cammarota
GBGiovanna Branca
Giovanna Branca
FAFausta Ardito
Fausta Ardito
Maurizio SanguinettiMaurizio Sanguinetti
Maurizio Sanguinetti
Gianluca IaniroGianluca Ianiro
Gianluca Ianiro
GGGiovanni Gasbarrini
Giovanni Gasbarrini

18 March 2004 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
GCGiovanni Cammarota
Giovanni Cammarota
AMA. Martino
A. Martino
GPG. Pirozzi
G. Pirozzi
Rossella CianciRossella Cianci
Rossella Cianci
GBG. Branca
G. Branca
GGG. Gasbarrini
G. Gasbarrini
Background : Helicobacter pylori infection may persist after both first- and second-line current treatments. Aim : To assess the efficacy of a third-line, culture-guided treatment approach for the eradication of H. pylori. Methods : Patterns of resistance were analysed in H. pylori isolates from 94 consecutive patients in whom H. pylori infection had persisted after two eradication attempts. Using the epsilometer test, susceptibility analysis was performed for amoxicillin, clarithromycin, metronidazole, tetracycline and levofloxacin. Patients were then treated with a culture-guided, third-line regimen: 89 patients with a 1-week quadruple regimen including omeprazole, bismuth, doxycycline and amoxicillin, and five patients with a 1-week triple regimen containing omeprazole, amoxicillin and levofloxacin or clarithromycin. Results : Ninety-four subjects (100%) were resistant to metronidazole, 89 (95%) to clarithromycin, 29 (31%) to levofloxacin and five (5%) to tetracycline. No resistance to amoxicillin was found in any patient. Overall, H. pylori eradication was obtained in 90% of subjects. The quadruple regimen was effective in 81 patients (92% by per protocol and 91% by intention-to-treat analysis). Four patients (80%, both per protocol and intention-to-treat analysis) were H. pylori-negative after the triple regimen. Conclusions : A culture-guided, third-line therapeutic approach is effective for the eradication of H. pylori. Furthermore, the 1-week doxycycline- and amoxicillin-based quadruple regimen is a good third-line ‘rescue’ treatment option.